Comprehensive Study Notes on DVT and Pulmonary Embolism Management

Pathophysiology and Complications of Venous Thromboembolism

• Deep Vein Thrombosis (DVT) is the formation of a blood clot within a deep vein.

• Approximately $80\%$ of DVT cases develop in the deep or superficial veins of the calf.

• The most serious complication of a Venous Thromboembolism (VTE) is a Pulmonary Embolism (PE).

• A Pulmonary Embolism occurs when a clot breaks loose from its original site and travels through the venous system.

• The clot moves to the right side of the heart and eventually lodges in the pulmonary arteries.

• This blockage obstructs blood flow to the lungs, which is a life-threatening condition.

Virchow’s Triad

• The development of a DVT is generally attributed to three factors known as Virchow’s Triad:

  • Endothelial Damage: This occurs due to damage to the lining of the blood vessel, which activates the body's natural clotting response.

  • Venous Stasis: This refers to slowed or pooled blood within the veins, which increases the likelihood of clot formation.

  • Hypercoagulability: This occurs when the blood becomes more likely to clot than is normal.

Risk Factors for DVT and PE

• Orthopedic Surgery: Patients undergoing hip surgery or total knee replacements are among the most concerning high-risk groups. The physical injury to vessels during surgery combined with decreased mobility postoperatively are major risk factors. These patients typically receive prophylactic anticoagulants and utilize compression devices.

• Heart Failure: Reduced cardiac output slows venous blood flow, which leads to increased venous stasis and a higher risk of clot formation.

• Immobility: This is one of the most common risk factors and results from bed rest, prolonged sitting, or long hospitalizations. Prevention should begin immediately upon admission.

• Pregnancy: Pregnancy causes an increase in clotting factors and places physical pressure on pelvic veins, which slows venous return.

• Medications: Oral contraceptives containing estrogen increase the risk for hypercoagulability.

• Cancer: Both the presence of cancer and various cancer treatments increase the tendency for clot formation.

• Genetics: Factor V Leiden is a common inherited genetic mutation that causes hypercoagulability. It involves a clotting protein that is resistant to natural inactivation. It affects approximately $3\%$ to $8\%$ of the population. While many carriers never develop a clot, the risk increases with age and combinations of other risk factors.

• Lifestyle and Age: Smoking damages blood vessels and promotes abnormal clotting. Obesity leads to decreased mobility and increased venous pressure. Older adults are at higher risk due to vascular changes and a higher incidence of chronic illnesses.

Clinical Assessment and Symptoms of DVT

• A significant challenge with DVT is that signs and symptoms are often nonspecific or mild, and may be mistaken for other conditions.

• Asymptomatic Presentation: Some patients may have a clot with few or no obvious symptoms.

• Key Assessment Findings:

  • Unilateral Leg Swelling: Edema typically occurs in only one leg. Nurses must compare both extremities to identify differences.

  • Pain and Tenderness: Patients often describe aching, soreness, or discomfort, usually in the calf area.

  • Warmth: Affected areas may feel warmer to the touch than surrounding tissue.

  • Induration: This refers to firm or hard tissue caused by inflammation along the vein.

  • Circumference Changes: Nurses should measure and compare the circumference of the right and left calves or thighs over time. Increasing size may indicate worsening clot formation.

• Prohibited Actions: Nurses must never massage or vigorously manipulate an extremity if a DVT is suspected. Massaging the area can dislodge the clot and trigger a pulmonary embolism.

Laboratory Testing for DVT

• Laboratory tests support a diagnosis but must be interpreted alongside symptoms and imaging.

• D-dimer Test: This measures fibrin degradation products, which are protein fragments released when the body breaks down a blood clot via fibrinolysis.

  • A value greater than $0.4$ is generally considered positive.

  • An elevated level suggests clot formation and breakdown is occurring somewhere in the body.

  • A positive D-dimer does not confirm DVT location and can produce false positives due to surgery, pregnancy, infection, inflammation, or cancer.

• Complete Blood Count (CBC): Used to assess hemoglobin, hematocrit, and white blood cell counts to check for infection or inflammation.

• Coagulation Studies: Tests include Prothrombin Time ($PT$), Activated Partial Thromboplastin Time ($APTT$), and Platelet Count. These establish a baseline before starting anticoagulation therapy.

Diagnostic Imaging for DVT

• Venous Duplex Ultrasound: This is the preferred, first-line, and most common diagnostic tool. It uses high-frequency sound waves to create real-time images of blood flow. It is non-invasive, painless, and does not require contrast dye. It allows providers to see the clot and the degree of obstruction.

• Doppler Flow Study: Often part of the ultrasound, this uses sound waves to measure the movement of blood. Normal circulation produces an audible sound; little or no sound indicates an obstruction.

• Venogram: This is an invasive procedure involving the injection of contrast dye into the vein followed by imaging. It is used less frequently today and is typically reserved for cases where ultrasound results are unclear but suspicion remains high.

Pharmacological Management: Anticoagulants

• The goal of treatment is to prevent the clot from enlarging, prevent new clots from forming, and reduce the risk of PE. Anticoagulants do not dissolve existing clots.

• Unfractionated Heparin:

  • Administered intravenously ($IV$) for acute DVT.

  • Requires close monitoring of $APTT$ levels. The therapeutic range is typically $47$ to $70\,\text{seconds}$.

  • If $APTT$ is too low, the risk of clot formation increases; if it is too high, the risk of bleeding increases.

  • Antidote: Protamine Sulfate.

  • Complication: Heparin-Induced Thrombocytopenia ($HIT$). This is an immune response that lowers platelet levels and can paradoxically increase clot formation. Platelet counts must be monitored regularly.

• Low Molecular Weight Heparin (e.g., Lovenox/Enoxaparin):

  • Given subcutaneously ($SC$) and dosed based on weight.

  • More predictable response than heparin and requires less lab monitoring.

  • Administered in the abdomen. Nurses should not expel the air bubble from the pre-filled syringe before injection.

• Warfarin (Coumadin):

  • Oral anticoagulant for long-term prevention.

  • Requires monitoring of $PT$ and International Normalized Ratio ($INR$).

  • The therapeutic goal for $INR$ is typically $2.0$ to $3.0$. For most DVT patients, the goal $PT$ is $1.5$ to $2.0\,\text{times}$ the normal value.

  • Takes $3$ to $4\,\text{days}$ to become effective. Patients often start on Heparin and Warfarin simultaneously (Bridging Therapy) until the therapeutic $INR$ is reached.

  • Antidote: Vitamin $K$.

• Factor XA Inhibitors (e.g., Eliquis/Apixaban):

  • Newer oral anticoagulants that block factor $XA$.

  • Advantages include fixed dosing and no requirement for routine $INR$ monitoring.

Warfarin Patient Education

• Adherence: Do not stop taking the medication abruptly unless directed by a provider. Take it at the same time every day.

• Dietary Consistency: Patients do not need to avoid Vitamin $K$ entirely but must maintain a consistent intake. High Vitamin $K$ foods include spinach, kale, and broccoli. Sudden fluctuations in intake can alter $INR$ levels.

• Safety: Patients should wear a medical alert bracelet.

• Interactions: Avoid alcohol, which alters metabolism and increases bleeding risk. Consult a provider before starting any new medications or herbal supplements.

• Medical Procedures: Inform providers/dentists of anticoagulant use before any surgery or dental work.

• Signs of Bleeding to Report:

  • Prolonged bleeding from small cuts.

  • Frequent nosebleeds or bleeding gums.

  • Unusual bruising that continues to enlarge.

  • Hematuria (red/brown urine).

  • Melena (black, tarry stools) which indicates an upper GI bleed.

  • Hematochezia (red stools) which indicates a lower GI bleed.

  • Vomiting blood.

  • Pregnancy status (Warfarin can affect fetal development).

Nursing Care and Prevention of DVT

• Mobility: Encourage early ambulation as soon as it is deemed safe by the provider and anticoagulation has started. This promotes venous return.

• Bed Rest Positioning: For patients on bed rest, encourage ankle pumps, dorsiflexion, and plantar flexion exercises. Elevate the legs to promote return to the heart, but do not place pillows directly under the knees as this can compress veins.

• Compression: Apply prescribed thigh-high anti-embolism stockings or Sequential Compression Devices ($SCDs$). Ensure proper fit and remove periodically to assess skin integrity.

• Hydration and Diet: Encourage adequate fluid intake to reduce blood viscosity. Increase fiber intake to prevent constipation and straining (which increases pressure).

• Avoid Restricted Flow: Teach patients not to cross their legs in bed or while sitting.

Endovascular and Surgical Procedures

• Thrombectomy: The physical removal of a clot from the vessel to restore blood flow quickly.

• Ultrasound-Assisted Thrombolysis: Uses high-frequency ultrasound waves combined with clot-dissolving medications (e.g., $TPA/Streptokinase$) to break up a thrombus.

• Inferior Vena Cava (IVC) Filter: A small device inserted through the femoral vein into the IVC to trap clots before they reach the lungs. Used when anticoagulation is contraindicated or ineffective.

Pulmonary Embolism (PE): Pathophysiology and Red Flags

• An embolus is a substance (clot, fat, air, etc.) that travels through the bloodstream and lodges in a pulmonary vessel, blocking flow.

• Effect: Obstruction prevents oxygen exchange, leading to systemic oxygenation decrease and pulmonary tissue hypoxia.

• Types of Emboli:

  • Thrombus: Most common (from DVT).

  • Fat Embolus: Associated with long bone fractures or orthopedic trauma.

  • Air Embolus: Can occur during central line insertion/removal or IV complications.

  • Septic Embolus: From bacterial invasion of a thrombus.

  • Amniotic Fluid Embolus: A rare obstetric emergency.

• Red Flag Symptoms: Sudden shortness of breath (dyspnea), sharp or pleuritic chest pain (worsens with deep breaths), and feelings of impending doom or extreme anxiety.

Clinical Presentation of PE

• Cardiac Findings: Tachycardia, heart murmurs ($S3$ or $S4$), distended neck veins ($JVD$), diaphoresis, and syncope (fainting).

• Respiratory Findings: Tachypnea (rapid breathing), dry cough, hemoptysis (bloody sputum), and adventitious sounds like crackles or a pleural friction rub.

• Systemic Findings: Petechiae (small purple spots over the chest), cyanosis (bluish skin/lips), and low-grade fever.

Diagnostic Evaluation for PE

• Arterial Blood Gases (ABGs):

  • Initially, patients often show Respiratory Alkalosis ($PaCO_2$ decreases) due to hyperventilation.

  • As the condition worsens, tissue hypoxia may lead to lactic acid accumulation and Metabolic Acidosis.

• MDCTA (Multidetector Computed Tomographic Angiography): This is the gold standard criterion for diagnosing PE. It uses IV contrast to visualize the vessels.

• VQ Scan (Ventilation-Perfusion Scan): Evaluates air movement vs. blood flow. Used if the patient cannot tolerate CT contrast dye.

• Electrocardiogram (EKG): Used to rule out myocardial infarction and check for signs of right heart strain.

Management of Pulmonary Embolism

• Immediate Nursing Priorities: Administer oxygen, establish IV access, and monitor vitals continuously.

• Medications:

  • Anticoagulation: Immediate Heparin drip, followed by 3-6 months of oral anticoagulants.

  • Inotropic Support: Dobutamine or Digitalis to support cardiac function.

  • Diuretics: If fluid overload is present.

  • Thrombolytics: (e.g., Alteplase/TPA) used for life-threatening PE to actively dissolve the clot; carries high bleeding risk.

  • Anxiety Management: Morphine or sedatives to decrease oxygen demand and distress.

• Surgical Intervention:

  • Surgical Embolectomy: Invasive removal of the embolus from pulmonary arteries.

  • Transvenous Catheter Embolectomy: Less invasive removal using a catheter to break apart or pull out the clot.

Nursing Considerations for PE Patients

• Activity: Initially on bed rest. Cluster care to conserve the patient's energy and reduce oxygen demand.

• Bleeding Precautions: Especially critical after thrombolytics. Avoid IM injections and unnecessary venipunctures. Apply prolonged pressure to any puncture sites.

• Monitoring: Watch for worsening hypoxia, hemodynamic instability (hypotension), and respiratory failure.